mehmetaltanmd
@mehmetaltanmd
Thoracic/Head and Neck Medical Oncology
ID: 1169969562261118976
06-09-2019 13:44:25
1 Tweet
63 Followers
17 Following
Presented at #IASLC22 | Investigator-initiated trial selinexor & pembrolizumab demonstrated antitumor activity in patient subsets with metastatic NSCLC, with no new safety signals. 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.10… mehmetaltanmd MD Anderson Cancer Center CC: @Ramalingam, OncoAlert, IASLC
